Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Dcri-2400 Pratt Street, Room 0311-BOX 3850, Durham, NC 27710
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Rockstroh, J, Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Pang, P, McHutchison, J, Dieterich, D, and Sulkowski, M. "A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection: the Phase 3 ION-4 study." JOURNAL OF VIRAL HEPATITIS 22 (September 2015): 24-24.

Scholars@Duke

AASLD/IDSA HCV Guidance Panel, . "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus." Hepatology (Baltimore, Md.) 62, no. 3 (September 2015): 932-954. (Review)

PMID
26111063
Full Text

Naggie, S, Cooper, C, Saag, M, Workowski, K, Ruane, P, Towner, WJ, Marks, K, Luetkemeyer, A, Baden, RP, Sax, PE, Gane, E, Santana-Bagur, J, Stamm, LM, Yang, JC, German, P, Dvory-Sobol, H, Ni, L, Pang, PS, McHutchison, JG, Stedman, CAM, Morales-Ramirez, JO, Braeu, N, Jayaweera, D, Colson, AE, Tebas, P, Wong, DK, Dieterich, D, Sulkowski, M, and Investigators, I. "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1." NEW ENGLAND JOURNAL OF MEDICINE 373, no. 8 (August 20, 2015): 705-713.

Full Text

Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Puoti, M, Orkin, C, and Hunt, SL. "Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes." The Journal of Infectious Diseases 212, no. 3 (August 2015): 367-377.

PMID
25583164
Full Text

Naggie, S, Cooper, C, Saag, M, Workowski, K, Ruane, P, Towner, WJ, Marks, K, Luetkemeyer, A, Baden, RP, Sax, PE, Gane, E, Santana-Bagur, J, Stamm, LM, Yang, JC, German, P, Dvory-Sobol, H, Ni, L, Pang, PS, McHutchison, JG, Stedman, CAM, Morales-Ramirez, JO, Bräu, N, Jayaweera, D, Colson, AE, Tebas, P, Wong, DK, Dieterich, D, Sulkowski, M, and ION-4 Investigators, . "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1." The New England Journal of Medicine 373, no. 8 (August 2015): 705-713.

PMID
26196665
Full Text

Naggie, S, Cooper, C, Saag, M, Yang, JC, Stamm, LM, Pang, PS, McHutchison, JG, Dieterich, D, and Sulkowski, MS. "Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1." JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 18 (July 2015).

Full Text

Horner, SM, and Naggie, S. "Successes and Challenges on the Road to Cure Hepatitis C." Plos Pathogens 11, no. 6 (June 18, 2015): e1004854-null. (Review)

PMID
26087286
Full Text

Matthews, GV, Neuhaus, J, Bhagani, S, Mehta, SH, Vlahakis, E, Doroana, M, Naggie, S, Arenas-Pinto, A, Peters, L, Rockstroh, JK, and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group, . "Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial." Hiv Medicine 16 Suppl 1 (April 2015): 129-136.

PMID
25711331
Full Text

Naggie, S, Patel, K, Yang, L-Y, Chow, S-C, Johnson, V, Guyton, JR, Muir, AJ, Sulkowski, M, and Hicks, C. "Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals." Open forum infectious diseases 2, no. 2 (April 2015): ofv066-.

PMID
26110167
Full Text

Naggie, S, Alam, I, Manch, RA, Reindollar, R, Slim, J, Prabhakar, A, Lauwers, K, Donovan, C, Tandon, N, Forlenza, JB, and Brown, K. "Effectiveness of Simeprevir (SMV) - Containing Regimens Among Patients With Chronic Hepatitis C Virus (HCV) in Various US Practice Settings: Interim Analysis of the Sonet Study." April 2015.

Scholars@Duke

Pages